Pieris Pharmaceuticals Inc (NASDAQ:PIRS)’s traded shares stood at 1.23 million during the last session, with the company’s beta value hitting 0.48. At the close of trading, the stock’s price was $0.19, to imply an increase of 3.03% or $0.0 in intraday trading. The PIRS share’s 52-week high remains $1.52, putting it -700.0% down since that peak but still an impressive 26.32% since price per share fell to its 52-week low of $0.14. The company has a valuation of $19.15M, with an average of 1.94 million shares in intraday trading volume over the past 10 days and average of 606.23K shares over the past 3 months.
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) trade information
After registering a 3.03% upside in the last session, Pieris Pharmaceuticals Inc (PIRS) has traded red over the past five days. The stock hit a weekly high of 0.2200, jumping 3.03% in its intraday price action. The 5-day price performance for the stock is -7.76%, and 20.61% over 30 days. With these gigs, the year-to-date price performance is 6.43%. Short interest in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) saw shorts transact 70720.0 shares and set a 0.23 days time to cover.
Pieris Pharmaceuticals Inc (PIRS) estimates and forecasts
Looking at statistics comparing Pieris Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Pieris Pharmaceuticals Inc (PIRS) shares are -36.72% down over the last 6 months, with its year-to-date growth rate higher than industry average at 22.22% against 12.60%. The rating firms project that company’s revenue will grow 23.50% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is $2.24 million. Meanwhile, for the quarter ending Mar 2024, a total of 1 analyst(s) estimate revenue growth to $2.24 million.Earnings reports from the last fiscal year show that sales brought in $5.85 million and $6.5 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -61.70% before dropping -65.50% in the following quarter.
PIRS Dividends
Pieris Pharmaceuticals Inc has its next earnings report out between March 28 and April 01. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Pieris Pharmaceuticals Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Pieris Pharmaceuticals Inc (NASDAQ:PIRS)’s Major holders
Pieris Pharmaceuticals Inc insiders hold 7.45% of total outstanding shares, with institutional holders owning 39.44% of the shares at 42.62% float percentage. In total, 39.44% institutions holds shares in the company, led by BVF Inc.. As of Jun 29, 2023, the company held over 20.61 million shares (or 20.85% of shares), all amounting to roughly $3.41 million.
The next major institution holding the largest number of shares is Lynx1 Capital Management Lp with 9.78 million shares, or about 9.89% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $1.62 million.
We also have Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Pieris Pharmaceuticals Inc (PIRS) shares. Going by data provided on Jun 29, 2023, Vanguard Extended Market Index Fund holds roughly 0.87 million shares. This is just over 0.88% of the total shares, with a market valuation of $0.14 million. Data from the same date shows that the other fund manager holds a little less at 0.35 million, or 0.36% of the shares, all valued at about 0.3 million.
